Human papillomavirus vaccines;Human papillomavirus (HPV) aşilari

Journal of the Turkish German Gynecology Association

Volumn 7, Issue 3, 2006, Pages 250-255

  Arvas, Macit ^a   Gezer, Altay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cervical cancer; HPV; Prophylaxis; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; IMMUNOGENICITY; PROPHYLAXIS; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION;

EID: 33750411040     PISSN: 13090399     EISSN: 13090380     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res 2002;89(2):183-90.
2. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005;18;23(17-18): 2388-94.
3. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;17;91(6):506-11.
4. Franco EL, Villa LL, Sobrinho JP et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180(5):1415-23.
5. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;5;102(5A):3-8.
6. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; (31):14-9.
7. Chellappan S, Kraus VB, Kroger B et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 1992;15;89(10):4549-53.
8. Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
9. Jansen KU, Rosolowsky M, Schultz LD et al. Vaccination with yeast expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995;13: 1509-14.
10. Koutsky LA, Ault KA, Wheeler CM et al. Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347(21):1645-51.
11. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6(5):271-8.
12. Harper DM, Franco EL, Wheeler C et al. GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364(9447):1757-65.
13. Monsenego J: Prevention of cervical cancer: Challenges and perspectives of HPV Prophylactic vaccines. In Monsenego J (ed): Emerging Issues in HPV infections. From Science to Practice. Karger. Basel, 2006, pp 184-205.
14. Donnelly JJ, Martinez D, Jansen KU et al. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996;173:314-20.
15. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9(1):37-48.
16. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003 Aug 13;290(6):781-9.
17. Bozon M. Sexuality, gender, and the couple: a sociohistorical perspective. Annu Rev Sex Res 2001;12:1-32.
18. Anhang R, Wright TC Jr, Smock L, Goldie SJ. Women's desired information about human papillomavirus. Cancer 2004;100(2):315-20.
19. Selvakumar R, Borenstein LA, Lin YL et al. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus induced papillomas. J Virol 1995;69:602-5.
20. Jensen ER, Selvakumar R, Shen H et al. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol 1997;71:8467-74.
21. Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
22. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.